Invasive pneumococcal infections among persons with and without underlying medical conditions: Implications for prevention strategies
Open Access
- 22 July 2008
- journal article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 8 (1), 96
- https://doi.org/10.1186/1471-2334-8-96
Abstract
Background The 23-valent pneumococcal polysaccharide vaccine (PPV23) is recommended for persons aged < 65 years with chronic medical conditions. We evaluated the risk and mortality from invasive pneumococcal disease (IPD) among persons with and without the underlying medical conditions which are considered PPV23 indications. Methods Population-based data on all episodes of IPD (positive blood or cerebrospinal fluid culture) reported by Finnish clinical microbiology laboratories during 1995–2002 were linked to data in national health care registries and vital statistics to obtain information on the patient's preceding hospitalisations, co-morbidities, and outcome of illness. Results Overall, 4357 first episodes of IPD were identified in all age groups (average annual incidence, 10.6/100,000). Patients aged 18–49 and 50–64 years accounted for 1282 (29%) and 934 (21%) of IPD cases, of which 372 (29%) and 427 (46%) had a current PPV23 indication, respectively. Overall, 536 (12%) IPD patients died within one month of first positive culture. Persons aged 18–64 years accounted for 254 (47%) of all deaths (case-fatality proportion, 12%). Of those who died 117 (46%) did not have a vaccine indication. In a survival model, patients with alcohol-related diseases, non-haematological malignancies, and those aged 50–64 years were most likely to die. Conclusion In the general population of non-elderly adults, almost two-thirds of IPD and half of fatal cases occurred in persons without a recognised PPV23 indication. Policymakers should consider additional prevention strategies such as lowering the age of universal PPV23 vaccination and introducing routine childhood pneumococcal conjugate immunisation which could provide substantial health benefits to this population through indirect vaccine effects.This publication has 45 references indexed in Scilit:
- Trends and geographical variation in invasive pneumococcal infections in FinlandScandinavian Journal of Infectious Diseases, 2008
- Invasive pneumococcal disease in Portugal prior to and after the introduction of pneumococcal heptavalent conjugate vaccineFEMS Immunology & Medical Microbiology, 2007
- Preventability of Invasive Pneumococcal Disease and Assessment of Current Polysaccharide Vaccine Recommendations for Adults: United States, 2001–2003Clinical Infectious Diseases, 2006
- Reduction in selective under-ascertainment bias in population-based estimates of cancer patient survival by age adjustmentEuropean Journal of Cancer, 2005
- The Influence of Chronic Illnesses on the Incidence of Invasive Pneumococcal Disease in AdultsThe Journal of Infectious Diseases, 2005
- Invasive Pneumococcal Infections in Denmark from 1995 to 1999: Epidemiology, Serotypes, and ResistanceClinical and Vaccine Immunology, 2002
- Clinical Efficacy of Pneumococcal Vaccine in the ElderlyAmerican Journal Of Medicine, 1997
- Hospital Discharge Register Data in the Assessment of Trends in Acute Myocardial InfarctionAnnals of Medicine, 1995
- Data Quality and Quality Control of a Population-Based Cancer Registry: Experience in FinlandActa Oncologica, 1994
- Piecewise Exponential Models for Survival Data with CovariatesThe Annals of Statistics, 1982